Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients

Affiliations

• ¹ Parkinson's Disease Expert Centre, Toulouse University Hospital, France.
• ² University of Toulouse, Mathematics Departement, Toulouse, France.
• ³ Parkinson's Disease Expert Centre, Toulouse University Hospital, France; French Reference Center for Multiple System Atrophy, Neurology Department, Toulouse University Hospital and Institute of Metabolic and Cardiovascular Diseases INSERM UMR 1297, Toulouse, France.
• ⁴ French Reference Center for Multiple System Atrophy, Neurology Department, Toulouse University Hospital and Institute of Metabolic and Cardiovascular Diseases INSERM UMR 1297, Toulouse, France; Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse 3, CHU of Toulouse, Toulouse, France.
• ⁵ French Reference Center for Multiple System Atrophy, Neurology Department, Toulouse University Hospital and Institute of Metabolic and Cardiovascular Diseases INSERM UMR 1297, Toulouse, France; Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse 3, CHU of Toulouse, Toulouse, France. Electronic address: margheritafabbrimd@gmail.com.